Dimethyl fumarate, a small molecule drug for psoriasis, inhibits Nuclear Factor-kappaB and reduces myocardial infarct size in rats

Persistent Nuclear Factor-kappaB (NF-kappaB) activation is hypothesized to contribute to myocardial injuries following ischemia-reperfusion. Because inhibition or control of NF-kappaB signaling in the heart probably confers cardioprotection, we determined the potency of the NF-kappaB inhibitor dimet...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of pharmacology Vol. 586; no. 1-3; pp. 251 - 258
Main Authors Meili-Butz, Silvia, Niermann, Thomas, Fasler-Kan, Elizaveta, Barbosa, Vania, Butz, Nicole, John, Dietlinde, Brink, Marijke, Buser, Peter T, Zaugg, Christian E
Format Journal Article
LanguageEnglish
Published Netherlands 31.05.2008
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Persistent Nuclear Factor-kappaB (NF-kappaB) activation is hypothesized to contribute to myocardial injuries following ischemia-reperfusion. Because inhibition or control of NF-kappaB signaling in the heart probably confers cardioprotection, we determined the potency of the NF-kappaB inhibitor dimethyl fumarate (DMF) in cardiovascular cells, and determined whether administration of DMF translates into beneficial effects in an animal model of myocardial infarction. In rat heart endothelial cells (RHEC), we analysed inhibitory effects of DMF on NF-kappaB using shift assay and immunohistofluorescence. In in vivo experiments, male Sprague Dawley rats undergoing left coronary artery occlusion for 45 min received either DMF (10 mg/kg body weight) or vehicle 90 min before ischemia as well as immediately before ischemia. After 120 min of reperfusion, the hearts were stained with phthalocyanine blue dye and triphenyltetrazolium chloride. Additionally, acute hemodynamic and electrophysiologic effects of DMF were determined in dose-response experiments in isolated perfused rat hearts. DMF inhibited TNF-alpha-induced nuclear entry of NF-kappaB in RHEC. In in vivo experiments, myocardial infarct size was significantly smaller in rats that had received DMF (20.7%+/-9.7% in % of risk area; n=17) than in control rats (28.2%+/-6.2%; n=15). Dose-response experiments in isolated perfused rat hearts excluded acute hemodynamic or electrophysiologic effects as mechanisms for the effects of DMF. DMF inhibits nuclear entry of NF-kappaB in RHEC and reduces myocardial infarct size after ischemia and reperfusion in rats in vivo. There was no indication that the beneficial effects of DMF were due to acute hemodynamic or electrophysiologic influences.
AbstractList Persistent Nuclear Factor-kappaB (NF-kappaB) activation is hypothesized to contribute to myocardial injuries following ischemia-reperfusion. Because inhibition or control of NF-kappaB signaling in the heart probably confers cardioprotection, we determined the potency of the NF-kappaB inhibitor dimethyl fumarate (DMF) in cardiovascular cells, and determined whether administration of DMF translates into beneficial effects in an animal model of myocardial infarction. In rat heart endothelial cells (RHEC), we analysed inhibitory effects of DMF on NF-kappaB using shift assay and immunohistofluorescence. In in vivo experiments, male Sprague Dawley rats undergoing left coronary artery occlusion for 45 min received either DMF (10 mg/kg body weight) or vehicle 90 min before ischemia as well as immediately before ischemia. After 120 min of reperfusion, the hearts were stained with phthalocyanine blue dye and triphenyltetrazolium chloride. Additionally, acute hemodynamic and electrophysiologic effects of DMF were determined in dose-response experiments in isolated perfused rat hearts. DMF inhibited TNF-alpha-induced nuclear entry of NF-kappaB in RHEC. In in vivo experiments, myocardial infarct size was significantly smaller in rats that had received DMF (20.7%+/-9.7% in % of risk area; n=17) than in control rats (28.2%+/-6.2%; n=15). Dose-response experiments in isolated perfused rat hearts excluded acute hemodynamic or electrophysiologic effects as mechanisms for the effects of DMF. DMF inhibits nuclear entry of NF-kappaB in RHEC and reduces myocardial infarct size after ischemia and reperfusion in rats in vivo. There was no indication that the beneficial effects of DMF were due to acute hemodynamic or electrophysiologic influences.
Author Barbosa, Vania
Zaugg, Christian E
Fasler-Kan, Elizaveta
John, Dietlinde
Meili-Butz, Silvia
Butz, Nicole
Buser, Peter T
Niermann, Thomas
Brink, Marijke
Author_xml – sequence: 1
  givenname: Silvia
  surname: Meili-Butz
  fullname: Meili-Butz, Silvia
  email: Silvia.Meili@unibas.ch
  organization: University Hospital Basel, Department of Research, Cardiobiology Laboratories, Switzerland. Silvia.Meili@unibas.ch
– sequence: 2
  givenname: Thomas
  surname: Niermann
  fullname: Niermann, Thomas
– sequence: 3
  givenname: Elizaveta
  surname: Fasler-Kan
  fullname: Fasler-Kan, Elizaveta
– sequence: 4
  givenname: Vania
  surname: Barbosa
  fullname: Barbosa, Vania
– sequence: 5
  givenname: Nicole
  surname: Butz
  fullname: Butz, Nicole
– sequence: 6
  givenname: Dietlinde
  surname: John
  fullname: John, Dietlinde
– sequence: 7
  givenname: Marijke
  surname: Brink
  fullname: Brink, Marijke
– sequence: 8
  givenname: Peter T
  surname: Buser
  fullname: Buser, Peter T
– sequence: 9
  givenname: Christian E
  surname: Zaugg
  fullname: Zaugg, Christian E
BackLink https://www.ncbi.nlm.nih.gov/pubmed/18405893$$D View this record in MEDLINE/PubMed
BookMark eNo1kD1PwzAYhD0U0Q_4Bwh5YmrC6zhu4hEKBaQKlu7VG-cNdXE-sJOhjPxyIgHT6aTn7qSbs0nTNsTYlYBYgFjdHmM6dgf0cQKQx5DEIPMJmwGINEq01lM2D-EIAEon6pxNRZ6CyrWcse8HW1N_ODleDTV67GnJkYcaneN168gMjnjph3detZ53ofUWgw1LbpuDLWwf-OtgHKHnGzR966MP7Dq859iU3FM5GAq8PrUGfWnRjakKvel5sF80Gj4Ohgt2VqELdPmnC7bbPO7Wz9H27ellfbeNOpXKiBJjZClyZVBnBnRCq7SC1YoKzPKslEZCLkinErRSIhcpZcYUUiiVYVVAJRfs5re28-3nQKHf1zYYcg4baoewzyBTQqtkBK__wKGoqdx33o7PnPb_p8kflYdyFQ
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.ejphar.2008.02.038
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EndPage 258
ExternalDocumentID 18405893
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
--K
--M
-~X
.55
.~1
0R~
1B1
1RT
1~.
1~5
4.4
457
4G.
53G
5GY
5RE
5VS
7-5
71M
8P~
9JM
AABNK
AACTN
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAXKI
AAXLA
AAXUO
ABCQJ
ABFNM
ABFRF
ABJNI
ABMAC
ABXDB
ABZDS
ACDAQ
ACGFO
ACGFS
ACIUM
ACRLP
ADBBV
ADEZE
ADMUD
AEBSH
AEFWE
AEKER
AENEX
AFKWA
AFTJW
AFXIZ
AGUBO
AGWIK
AGYEJ
AIEXJ
AIKHN
AITUG
AJOXV
AKRWK
ALCLG
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
AXJTR
BKOJK
BLXMC
C45
CGR
CS3
CUY
CVF
DU5
EBS
ECM
EFJIC
EIF
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FIRID
FNPLU
FYGXN
G-Q
HMQ
HZ~
IHE
J1W
K-O
KOM
L7B
M2V
M34
M41
MO0
MOBAO
N9A
NPM
O-L
O9-
OAUVE
OGGZJ
OVD
OZT
P-9
P2P
PC.
Q38
RIG
ROL
RPZ
SDF
SDG
SDP
SES
SPCBC
SSN
SSP
T5K
TEORI
X7M
~G-
7X8
ID FETCH-LOGICAL-p543-e2cc3d185ca97c092e64f066eba787d3c3081e94309551814e7ccb31557afb0f3
ISSN 0014-2999
IngestDate Sat Aug 17 01:16:24 EDT 2024
Sat Sep 28 07:57:12 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 1-3
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-p543-e2cc3d185ca97c092e64f066eba787d3c3081e94309551814e7ccb31557afb0f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 18405893
PQID 70751952
PQPubID 23479
PageCount 8
ParticipantIDs proquest_miscellaneous_70751952
pubmed_primary_18405893
PublicationCentury 2000
PublicationDate 2008-May-31
20080531
PublicationDateYYYYMMDD 2008-05-31
PublicationDate_xml – month: 05
  year: 2008
  text: 2008-May-31
  day: 31
PublicationDecade 2000
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle European journal of pharmacology
PublicationTitleAlternate Eur J Pharmacol
PublicationYear 2008
SSID ssj0005925
Score 1.9074328
Snippet Persistent Nuclear Factor-kappaB (NF-kappaB) activation is hypothesized to contribute to myocardial injuries following ischemia-reperfusion. Because inhibition...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 251
SubjectTerms Animals
Dermatologic Agents - therapeutic use
Dimethyl Fumarate
Electrocardiography - drug effects
Electrophoretic Mobility Shift Assay
Electrophysiology
Endothelial Cells - drug effects
Endothelial Cells - pathology
Fluorescent Antibody Technique
Fumarates - therapeutic use
Heart Rate - drug effects
In Vitro Techniques
Male
Myocardial Infarction - drug therapy
Myocardial Infarction - pathology
Myocardial Reperfusion Injury - pathology
Myocardium - cytology
Myocardium - pathology
NF-kappa B - antagonists & inhibitors
Nuclear Proteins - metabolism
Psoriasis - drug therapy
Rats
Rats, Sprague-Dawley
Title Dimethyl fumarate, a small molecule drug for psoriasis, inhibits Nuclear Factor-kappaB and reduces myocardial infarct size in rats
URI https://www.ncbi.nlm.nih.gov/pubmed/18405893
https://search.proquest.com/docview/70751952
Volume 586
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6FcuGCKM9CgT2gXpyNEj9i75FCowpKqISLcrPW613VJXEsO6mUHjjwN_izzD4cu6IVj4sVW4q98XzZ-XZ25huE3ohoKIMgdIlgbEh8mY0JlZkk2YiKgErmZ0IVOH-ajo_P_A-zYNbr_exkLa1X6YBf3VhX8j9WhWtgV1Ul-w-W3d4ULsBnsC8cwcJw_Csbv89VA-jN3JEqUZqZTnfMqRdqv3lhGt8KJ6vWJlmyrJcwqNqoCuTFeZ6qXYOpUjRmlTPRnXfIN1aW7NCknStZV1E7iw04vEpXmMCo4Z-xcur8SquNwEPrW4P7luiWrTp2m3Is8nlODte6m6zzJZ9f5lv_MM2VtzC8upO_pBUj67moyEcTtNUZaZdi1YYUWJUua82Gv7LC3rCJaETNZnw7S498Am6SdmfpwCpmWzgSrzvrWs1aYc-iG32DCVNcDMSF-t02jdYdDI26zHUp7unnZHJ2cpLER7P4DrrrhjRQK_vB907-EHVtewwz2KYuUycP_v6M21cwmsnED9B9uwTBbw2edlFPFA_Rwamx0qaP47Ykr-7jA3zasd8j9KMBHW5A18cMa8jhBnJYQQ4D5PAWcn3cAA5bwOFrgMMAOGwBh1vAYQs4rAAHJ1gB7jGKJ0fxu2NiG3mQMvA9IlzOvQyIIWc05EPqirEvgeqKlIG7yDzuAS8Vqg8AVfqAI1-EnKceMN2QyXQovSdop1gW4hnCaeBlinP6I8l94Jo08qJxFvEQCJjkku2h181bTmCeVJtfrBDLdZ2EwI1HNHD30FPz8pPSyLkkKsYRAG1__sfvvkD3Wrzuo51VtRYvgZOu0lcaG78AxOaVcg
link.rule.ids 315,786,790,27957,27958
linkProvider Elsevier
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Dimethyl+fumarate%2C+a+small+molecule+drug+for+psoriasis%2C+inhibits+Nuclear+Factor-kappaB+and+reduces+myocardial+infarct+size+in+rats&rft.jtitle=European+journal+of+pharmacology&rft.au=Meili-Butz%2C+Silvia&rft.au=Niermann%2C+Thomas&rft.au=Fasler-Kan%2C+Elizaveta&rft.au=Barbosa%2C+Vania&rft.date=2008-05-31&rft.issn=0014-2999&rft.volume=586&rft.issue=1-3&rft.spage=251&rft.epage=258&rft_id=info:doi/10.1016%2Fj.ejphar.2008.02.038&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0014-2999&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0014-2999&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0014-2999&client=summon